These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32457604)

  • 1. Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy.
    Calderon-Ospina CA; Galvez JM; López-Cabra C; Morales N; Restrepo CM; Rodríguez J; Aristizábal-Gutiérrez FA; Velez-van-Meerbeke A; Laissue P; Fonseca-Mendoza DJ
    Front Pharmacol; 2020; 11():555. PubMed ID: 32457604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.
    Makowska M; Smolarz B; Bryś M; Forma E; Romanowicz H
    Int J Neurosci; 2021 Dec; 131(12):1147-1154. PubMed ID: 32567426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
    Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
    Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
    Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
    Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC; Hung SI; Carleton BC; Chung WH
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of adverse reactions to antiepileptic drugs.
    Fricke-Galindo I; Jung-Cook H; LLerena A; López-López M
    Neurologia (Engl Ed); 2018 Apr; 33(3):165-176. PubMed ID: 25976948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
    Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
    Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
    Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
    Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
    J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D Status in Russian Children and Adolescents: Contribution of Genetic and Exogenous Factors.
    Kondratyeva EI; Zakharova IN; Ilenkova NA; Klimov LY; Petrova NV; Zodbinova AE; Zhekaite EK; Chikunov VV; Dolbnya SV; Voronkova AY; Sherman VD; Loshkova EV; Melyanovskaya YL; Budzinskiy RM; Kuryaninova VA; Kutsev SI
    Front Pediatr; 2020; 8():583206. PubMed ID: 33330279
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
    Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
    Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
    JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome.
    Yaşar Ü
    Cent Eur J Immunol; 2018; 43(2):220-221. PubMed ID: 30135636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan.
    Maqbool H; Saleem T; Sheikh N; Ashfaq A
    Genet Res (Camb); 2022; 2022():1451007. PubMed ID: 35136381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
    Twardowschy CA; Werneck LC; Scola RH; Borgio JG; De Paola L; Silvado C
    Seizure; 2013 Apr; 22(3):194-7. PubMed ID: 23298603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.
    Silvado CE; Terra VC; Twardowschy CA
    Pharmgenomics Pers Med; 2018; 11():51-58. PubMed ID: 29636628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.